Recently back from the Perinatal Stem Cell Society Conference in Aspen, CO, I am excited to share new coverage of the stem cell market with you. At this event, experts from around the world shared cutting-edge research about perinatal tissues over the course of three days (March 2-4, 2016).
We also have interviews with stem cell executives released below, including an interview with Dr. Jon Rowley, Founder and CEO of RoosterBio, and Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics. Enjoy this exclusive new content!
Over March 2-4, 2016, dozens of world-renowned speakers presented their latest findings at the Perinatal Stem Cell Society Conference 2016, hosted by Kyle Cetrulo of Auxocell Laboratories and the Perinatal Stem Cell Society (IPLASS). To capture the best moments, this article presents the top 10 quotes from the event.
(Check out our photo album from the event on Flickr.)
This article is a Q&A interview with the Founder and CEO of RoosterBio, Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation. In this interview, we explore how RoosterBio is “radically changing the use of stem cells.”
In breaking news, Cynata announced it has entered into a strategic alliance with Regience K.K., who will have an exclusive 2-year option to license Cynata’s unique Cymerus™ technology in Japan and other Asian countries. Cynata’s Cymerus™ technology produces clinical-grade mesenchymal stem cells (MSCs) using induced pluripotent stem cells (iPSCs) as the source tissue, eliminating product variability and lowering manufacturing costs.
Mesoblast announced that it is launching the first allogeneic cell therapy to ever achieve full approval in Japan, a mesenchymal stem cell (MSC) product, TEMCELL® HS Inj. The product will be used for the treatment of acute graft versus host disease (aGVHD), sold through Mesoblast’s Japanese licensee, JCR Pharmaceuticals.
Pluristem is a biotechnology company that uses placental cells and a proprietary, 3D technology platform to develop cell therapies for a range of diseases. In this interview, Dr. Ofir and I discuss Pluristem’s placental-derived “PLX” cells, which are being explored for applications that include critical limb ischemia (CLI), acute radiation syndrome (ARS), incomplete bone marrow engraftment, and more. (*Dr. Ofir also attended the recent Perinatal Stem Cell Society Conference.)
“Mesenchymal Stem Cells – Advances & Applications” — Market Size, Segments, Trends, & Projections through 2020
Sourced from both perinatal and adult sources, MSCs are a leading type of stem cell being investigated for therapeutic applications. In addition to secreting factors that can stimulate tissue repair, MSCs can substantially alter their microenvironment, exerting effects that are anti-inflammatory and anti-fibrotic. Importantly, MSCs well-suited for use in the exponential growth area of 3D printing, because of their unusual capacity to form structural tissues. Learn about the growing market potential for this cell type.
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, AABB, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data.